Statement of the problem: Diabetes mellitus is a challenging problem in modern medicine. Over 347 million people worldwide suffer from diabetes. Polyneuropathy is the most common complication of diabetes mellitus (60-70% of patients). Its treatment still remains unresolved. The optimal therapy involves: blood glucose level control, anticonvulsants, antidepressants and opioid administration, though it does not change pathogenic pattern. It has been identified that tumor necrosis factor alpha (TNF-α) and renin-angiotensin aldosterone system (RAAS) play a significant role in Type I and Type II diabetes development The data collected in the present-day scientific literature indicate the essential pathogenic role of TNF-α in the development of diabetic neuropathy (DNP). In our study we use Aliskiren (renin inhibitor) to study modulatory impact on TNF-α.
Methodology & Theoretical Orientation: The study population consists of 15 individuals diagnosed with diabetes mellitus (T2DM) with DNP. The enrolled subjects take Aliskiren during 6 weeks. At the start of the trial and on completion of the six weeks period TNF-α level and C-peptide will be determined.
Findings: Aliskiren improves conditions of T2DM patients with DNP. Namely, the symptoms of neuropathy are reduced, the blood TNF-α level is reduced and C-peptide level is increased.
Conclusion & Significance: Our results confirm hypothesis that TNF-α may play a substantial role in the development and progression of type 2 diabetes mellitus as well as in pathogenesis of diabetic neuropathy. Aliskiren has modulatory impact on TNF-α, so we have results for clinical and pharmacological analysis of Aliskiren application in diabetic neuropathy.